- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00750282
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection/Exclusion of Cerebral Amyloid Beta in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
-
-
-
-
-
Berlin, Germany, 13125
-
-
Bayern
-
Erlangen, Bayern, Germany, 91054
-
München, Bayern, Germany, 81675
-
München, Bayern, Germany, 81377
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Germany, 45122
-
Jülich, Nordrhein-Westfalen, Germany, 52425
-
Münster, Nordrhein-Westfalen, Germany, 48149
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
-
Leipzig, Sachsen, Germany, 04103
-
-
-
-
Hyogo
-
Kobe, Hyogo, Japan, 650-0047
-
Kobe, Hyogo, Japan, 650-0017
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8603
-
-
-
-
-
Zürich, Switzerland, 8091
-
-
-
-
Arizona
-
Sun City, Arizona, United States, 85351
-
-
California
-
Stanford, California, United States, 94305
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
-
-
New York
-
Bronx, New York, United States, 10461
-
New York, New York, United States, 10016
-
New York, New York, United States, 10032
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study:
- Is a man or woman and is > 55 of age, whereby females must be without childbearing potential (confirmed by either: age >/= 60; or history of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start)
- Has at least 6 years of education
- Is able to provide informed consent, understand the information provided on the purpose and conduct of the trial and to comply with study procedures
- Possesses a general health that permits adequate compliance with all study procedures
- The subject, or the subject and caregiver (for probable AD patients) will be compliant and have a high probability of completing the study
- Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable AD patients)
Inclusion criteria for HV only:
- Has no evidence of cognitive impairment
- Has MRI brain scan that has been judged as "normal" (age- appropriate)
Inclusion criteria for patients with AD only:
- Presents with positive assessment for dementia of Alzheimer's type
- Does not fulfill the criteria Dementia with Lewy Bodies (DLB) or Vascular Dementia (VaD)
- MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease
- Has a caregiver that is willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver
Exclusion Criteria:
- Has any contraindication to MRI examination scan
- Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application
- Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma)
- is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable
- Has a history of exposure to any radiation >15 milli Sieverts (mSv)/year (e.g. occupational or radiation therapy)
- Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)
- Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical
- Has a brain tumor or other intracranial lesion, a disturbance of cerebro-spinal fluid (CSF) circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery
- Has an inflammatory or infectious central nervous system (CNS) disease, e.g. multiple sclerosis, HIV, syphilis, or Creutzfeldt-Jacob disease
- Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness
- Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function)
- Has a history of alcohol or drug abuse
- Has history of severe persistent depression
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Florbetaben (BAY94-9172)
|
Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth
Time Frame: 90 - 110 min after investigational medical product (IMP) injection
|
Part A: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan which was considered a match for specificity. Standard of truth was the onsite clinical diagnosis. Two Beta-Amyloid Plaque Load (BAPL) algorithms for assessing the normality/abnormality of beta-amyloid plaque load in the brain scans were used. Using algorithm A (Majority Read), a brain scan of a subject with a BAPL score of "1" (without beta-amyloid plaque load) or "2" (with minor beta-amyloid plaque load) was considered normal and a BAPL score of "3" (with significant beta-amyloid plaque load) was considered abnormal. Using algorithm B (Average), a brain scan of a subject with a BAPL score of "1" was considered normal and a brain scan with a BAPL score of "2" or "3" was considered abnormal. Algorithm B was used in Part B and in the final |
90 - 110 min after investigational medical product (IMP) injection
|
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.
Time Frame: 90 - 110 min after IMP injection
|
Part B: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan, ie,abnormal scan (BAPL scores "2" or "3") which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan, ie,normal scan (BAPL score "1") which was considered a match for specificity. The clinical diagnosis was established by an independent consensus panel (CP) of experts in dementia. Two independent sets of PET data reads were performed. The first set was performed by a panel of three readers who received live, instructor-led training on the visual assessment procedure. The second set was performed by a panel of five separate readers who were trained on the visual assessment procedure with electronic media. |
90 - 110 min after IMP injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment
Time Frame: 45 - 60 min and 110 - 130 min after IMP injection
|
PET scans from two additional imaging windows (45-60 min and 110-130 min) were visually assessed
|
45 - 60 min and 110 - 130 min after IMP injection
|
Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)
Time Frame: 45-60 min, 90-110 min, 110-130 min
|
The agreement between 3 blinded readers concerning the visual assessment of abnormality of the brain scan (based on BAPL score) was measured by the kappa coefficient.
Kappa values close to 1.0 indicate a high agreement while values close to 0 indicate random agreement.
|
45-60 min, 90-110 min, 110-130 min
|
Standard Uptake Value Ratios for Florbetaben Signal
Time Frame: 90-110 min post injection
|
The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, lateral temporal cortex, parietal cortex, anterior cingulate, posterior cingulate cortex, occipital cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake.
The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg).
These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.)
|
90-110 min post injection
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Bullich S, Roé-Vellvé N, Marquié M, Landau SM, Barthel H, Villemagne VL, Sanabria Á, Tartari JP, Sotolongo-Grau O, Doré V, Koglin N, Müller A, Perrotin A, Jovalekic A, De Santi S, Tárraga L, Stephens AW, Rowe CC, Sabri O, Seibyl JP, Boada M. Early detection of amyloid load using (18)F-florbetaben PET. Alzheimers Res Ther. 2021 Mar 27;13(1):67. doi: 10.1186/s13195-021-00807-6.
- Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 311741 (Other Identifier: company internal)
- 2007-002256-42 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Florbetaben (BAY94-9172)
-
Life Molecular Imaging SACompletedAlzheimer DiseaseUnited States, France, Japan, Australia, Germany
-
Life Molecular Imaging SACompletedAlzheimer Disease | Amyloid Beta-ProteinAustralia
-
Life Molecular Imaging SACompletedDown Syndrome | Amyloid Beta-proteinUnited States
-
New York State Psychiatric InstituteBayer; National Institute on Aging (NIA)CompletedLate Onset Alzheimer DiseaseUnited States
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States
-
BayerCompleted
-
Judit Pich MartínezTerminated
-
IRCCS Policlinico S. MatteoRecruiting
-
Adam BrickmanNational Institute on Aging (NIA)Completed
-
National Institute on Alcohol Abuse and Alcoholism...CompletedNormal PhysiologyUnited States